| CEO Name | Scott Wolchko |
| Nationality | United States |
| Net Worth Estimation | $15 million |
Scott Wolchko's estimated net worth of $15 million is primarily derived from his long-term executive role and equity holdings in Fate Therapeutics, a prominent biotechnology company. His compensation package includes salary, bonuses, and significant stock options, reflecting his leadership and contribution to the company's market growth.
Scott Wolchko, CEO of Fate Therapeutics, has an estimated net worth of $15,000,000, which is 7.5% above the biotechnology CEO minimum benchmark and 81.25% below the maximum. His net worth places him in the lower range compared to biotech CEOs whose net worth typically ranges from $10,000,000 to $80,000,000.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Scott Wolchko Performance in Fate Therapeutics
Scott Wolchko, CEO of Fate Therapeutics, drives strategic leadership and data-driven decision-making, accelerating the development of innovative cellular immunotherapies. Under his guidance, the company has expanded its clinical pipeline and achieved key regulatory milestones, enhancing investor confidence and market positioning. His performance has significantly advanced Fate Therapeutics' reputation as a leader in regenerative medicine and precision oncology.
Latest News
Fate Therapeutics Announces Leadership Transition and Promising Clinical Data
Bob Valamehr, Ph.D. MBA, succeeds Scott Wolchko as CEO in January 2025, while the company reports strong Phase 1 results for its off-the-shelf CAR-T therapy in lupus, with rapid B-cell depletion and improved disease scores in patients.
Source: http://www.globenewswire.com/news-release/2025/11/04/3180811/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html